StimGuard today said it appointed Stephen Deitsch as chief financial officer, effective Jan. 15.
Deitsch has 20 years of corporate financial leadership experience in medtech and healthcare. He replaces interim chief financial officer Gil Bao, who will transition into the role of director of strategy.
“We are excited that Steve will be joining StimGuard’s executive team as chief financial officer,” founder and CEO Laura Perryman said in a news release. “Steve is an accomplished financial executive in our industry, and his leadership experience and demonstrated track record of increasing shareholder value will be key as we transition to commercial stage and bring our differentiated and leading-edge CAN-Stim System to the U.S. urology market in 2020. Steve will nicely complement the recently announced StimGuard executive leadership team, that was previously successful in leading Stimwave a pain management venture to an annualized revenue run-rate of over $40 million.”
Deitsch most recently served as chief financial officer of BioScrip. He has also held a number of leadership roles at Zimmer Biomet, Lanx and Green Sun Medical.
“I am thrilled to join a truly innovative company providing a less invasive, physician office-based surgical option for those who suffer from overactive bladder and urinary incontinence. This innovative technology will improve patient outcomes and lower the cost of care,” Deitsch said. “In evaluating this opportunity, while drawn to StimGuard’s disruptive technology, it was also exciting to see a path to near term profitability and a capital-efficient business model. I look forward to working with Laura and the rest of the team to continue to create value for all of our stakeholders.”